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Synopsis  
Foreign-born individuals account for over 12% of the U.S. population, 
according to the most recent census data.  Since many vaccine-preventable 
outbreaks in the U.S. have been correlated with disease importation, Congress 
has mandated vaccinations for numerous immigrant populations.  It is essential 
for primary care physicians to be knowledgeable on the unique immunization-
related needs of foreign-born individuals, to recognize some of the cultural and 
linguistic challenges that immigrants have accessing healthcare, and remember 
to use each medical encounter as an opportunity to provide necessary 
vaccinations. 
 
Introduction 
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At the time of the 2000 Census, foreign-born individuals accounted for 
11.1% of the total U.S. population.1 By 2009, this percentage increased to 12% 
totaling 36.7 million foreign-born individuals in the U.S.2 The U.S. foreign-born 
population includes immigrants (legal permanent residents), humanitarian 
migrants (e.g., refugees), temporary migrants (e.g., students), and unauthorized 
migrants (undocumented individuals residing in the U.S.).  Persons born abroad 
to American parents or born in Puerto Rico or other U.S. Island Areas are not 
considered foreign-born.1  
Refugees constitute a special subset of the foreign-born population, 
because of the sociopolitical factors leading to their migration. From 2000 to 
2009, 618,090 refugees migrated to the U.S. from over 60 different countries. The 
top 10 countries of origin were Cuba, the former Soviet Union, Somalia, former 
Yugoslavia, Burma, Iraq, Iran, Liberia, Sudan, and Vietnam. Refugees in the U.S. 
resettle in some regions more often than others, and the states with the largest 
number of resettled refugees are Florida, California, Texas, New York, and 
Minnesota.3 
There is substantial evidence that many of the vaccine-preventable 
outbreaks in the U.S. have been directly related to disease importation.  In 2008, 
close to 90% of the measles cases in the US were either acquired overseas or 
imported cases, leading to 7 outbreaks and 135 infected persons.4  Even though 
rubella disease is less severe than measles, congenital rubella syndrome can be 
devastating and life-threatening.  Fortunately, only two cases were reported in 
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the U.S. in 2009.5  However, in one of the two cases, the individual was travelling 
throughout her first trimester in India and China.  For these reasons, Congress has 
mandated vaccinations for immigrant populations in the US to decrease the 
public health burden from imported vaccine-preventable diseases. 
As a whole, foreign-born individuals have unique immunization-related 
needs that can be influenced by country of origin, age of arrival to the U.S., and 
circumstances surrounding their migration (e.g., refugees/asylees, adoptees).  
Primary care physicians must be aware of these needs and be comfortable 
providing the appropriate services to this population. 
 
Start with the basics 
In the primary care setting, foreign-born patients may present with 
complicated medical and social histories, and it is important to keep in mind the 
standard age-appropriate preventive care recommendations that apply to all 
patients. Compared to their U.S. cohorts, foreign-born individuals may have 
more difficulty accessing healthcare due to cultural and linguistic barriers.6,7 
Foreign-born patients may be more likely to access healthcare for acute care 
rather than for health maintenance, so sick visits should be viewed as an 
opportunity to provide these important services, including vaccination.  Many of 
these patients will not return for a separate health maintenance visit, even if the 
recommendation is made. In many developing countries, the concept of a 
health maintenance visit is largely unknown, so the idea of returning to simply 
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discuss wellness issues may be viewed with skepticism, even if patients outwardly 
voice agreement with the follow-up plan. Vaccination should not be delayed 
due to mild respiratory tract infections or other acute illness, although 
vaccination should be deferred for moderate or severe illness.8  
Assessing Risk: Important Vaccine-Preventable Diseases for Foreign-Born 
Populations 
Knowing a patient’s country of origin can help to assess the patient’s level 
of risk for certain preventable diseases.  Unfortunately, for the sake of examining 
the incidence of disease in these populations, immigrants are usually grouped 
together as a single unit, even though the incidence and prevalence of 
diseases differs among particular subgroups.  In addition, it is also important for 
the primary care physician to have a general understanding of the cultural 
norms in these individuals, to better assess an individual’s risk for disease (i.e. the 
risk of sexually-transmitted infections in populations with a high prevalence of 
sexual abuse). 
Despite near total eradication of numerous vaccine-preventable diseases 
in the U.S., the 
 rest of the world has not been as fortunate.  In 2002, WHO (World Health 
Organization)  
estimated that 14% (1.4 million deaths) of the total global mortality in children 
under the age of  
5 years old was due to disease that could have been prevented with routine 
vaccination.  The  
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distribution of these deaths is seen in Figure 1.9 
In the following sections we will focus specifically on tuberculosis, viral hepatitis, 
and human papillomavirus. These conditions were selected for special emphasis 
due to the greater burden of disease caused by these infections among 
immigrant populations. 
Infectious Disease Burden:  TUBERCULOSIS 
Tuberculosis (TB) is very common in much of the world, with the continent 
of Africa having the largest number of high-prevalence nations. Continents with 
lowest rates of tuberculosis include North America, Europe, and Australia. 
According to the World Health Organization, the country with the highest 
incidence for the combined years of 2007-2008 was Swaziland in southern 
Africa, with an incidence of 510 per 100,000 population (compared to 2 per 
100,000 in the U.S.).10  
Although immunization against TB is not commonly performed (and not 
routinely recommended) in the U.S.,11 there are many parts of the world where 
for years children have been routinely given the BCG (Bacille Calmette-Guérin) 
vaccine to prevent TB. While the vaccine has not been shown to make a large 
epidemiologic impact on TB infection per se, it seems to confer some protection 
against serious TB disease among children, and may also protect against the 
development of leprosy.12 Prior vaccination with BCG can sometimes result in 
false positive results for the standard tuberculin skin test (TST).13 Since many 
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foreign-born individuals come from areas with endemic TB, further testing is 
necessary to identify these high-risk individuals. 
Two newer blood tests serve as alternatives to the TST and are unaffected 
by prior BCG vaccination: the ELISA-based QuantiFERON-TB Gold, which 
measures interferon gamma concentration in supernatant, and the enzyme-
linked immunospot (ELISpot; T-SPOT TB), which enumerates interferon-gamma-
secreting T cells. Both tests have better specificity than the TST, although the 
immunospot test appears to have higher sensitivity for detecting latent 
tuberculosis infection.13 Despite decreases in active TB cases for US-born 
individuals, the numbers of active TB cases among foreign-born individuals in the 
US is still relatively elevated and have remained stable over the years (Figures 
2,3).  Identification and treatment of these individuals is necessary to decrease 
the burden of tuberculosis disease.   Unfortunately, simple, inexpensive point-of-
care tests with this level of sensitivity and specificity are still not available.14   
Infectious Disease Burden:  HEPATITIS A 
Since the introduction of hepatitis A vaccination in 1995, cases of HAV in 
the U.S. have dropped 84%.17  However, hepatitis A remains endemic in many 
parts of the world. High prevalence regions include sub-Saharan Africa and 
parts of south Asia, where it is estimated that ≥90% of the population have 
serologic evidence of infection by age 10. Intermediate prevalence occurs in 
Latin America, northern Africa, and the Middle East (≥50% with evidence of 
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infection by age 15).18 Chronic hepatitis A has not been reported, although 10-
20% of symptomatic patients experience a prolonged or relapsing course.19 For 
all patients, but particularly those who have recently traveled from high-risk 
regions, hepatitis A should be considered in the setting of symptoms such as 
abdominal pain, fatigue, nausea, anorexia, urticaria and jaundice. It is 
important to note, however, that infected children may be asymptomatic; only 
about 30% of infected children exhibit symptoms (often non-specific flu-like 
symptoms), and viral shedding may continue in their stools for 6 months.19 
Infectious Disease Burden:  HEPATITIS B 
Hepatitis B is endemic in many regions of the world as well, including 
much of Eastern Europe, Asia, Africa, the Middle East, and the Pacific Islands 
(see Figure 4). Chronic hepatitis B infection can result in liver failure, cirrhosis, and 
hepatocellular carcinoma. Only 0.3-0.5% of the U.S. population is chronically 
infected with hepatitis B, but among foreign-born individuals, prevalence is 1.0-
2.6%.16 
People who come from countries with ≥2% hepatitis B prevalence are at 
greatest risk for both active and chronic hepatitis B infection.  These individuals 
should be screened via Hepatitis B surface antigen testing (HBsAg) and 
immunized if they are not infected (unless there is documentation that there has 
been prior completion of the immunization series). For foreign-born persons from 
high-risk countries, HBsAg testing is warranted even when there is a documented 
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history of immunization, because it is possible that infection could have occurred 
prior to immunization. In addition, testing is also recommended for U.S.-born 
persons who were not vaccinated as infants and whose parents were born in 
regions with ≥8% HBV endemicity (e.g., Peru, northern Brazil, Greenland, sub-
Saharan Africa, Saudi Arabia, and much of Asia and the Pacific Islands).16 For 
individuals with unknown hepatitis B immunization history, it is reasonable to 
consider testing for Hepatitis B surface antibody (HBsAb) before deciding to 
immunize; however, if the cost of serologic testing exceeds the cost of 
immunization, it might be more cost effective merely to vaccinate. 
Infectious Disease Burden:  HUMAN PAPILLOMAVIRUS 
There is clear evidence in the medical literature to support the direct 
relationship that human papilloma virus (HPV) has on the development of 
cancer, including cervical, vulvar, anal, penile and oropharyngeal. HPV has 
been recognized as the cause of essentially all cervical cancers.20-22 Even 
though the number of cervical cancer cases in the US are very low, cervical 
cancer affects many women worldwide.23,24 HPV vaccines that are available in 
the US and other countries have been shown to prevent the transmission of the 
high-risk HPV subtypes that pose the greatest risk to the development of cervical 
cancer.24  For many foreign-born individuals, they are likely to be behind in 
cervical cancer screening.  Administration of the HPV vaccine to this population 
at the earliest visit to the healthcare provider is essential in lowering the 
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incidence of cervical cancer. It is important to remember, however, that HPV 
immunization does not prevent infection of all oncogenic HPV subtypes (only 16 
and 18), nor does it treat infections that have already occurred prior to 
immunization. Therefore, Pap testing is still an essential component in the 
prevention of cervical cancer, regardless of HPV immunization status.  
Travel Medicine 
Foreign-born individuals may travel back and forth between the U.S. and 
their country of origin, or they may have frequent contact with other people 
who are from that part of the world. Consequently, it might be advisable to 
consider immunization against illnesses that are common in the country of origin, 
especially if the patient anticipates traveling there in the near future. The CDC 
has a comprehensive travel website (http://wwwnc.cdc.gov/travel/) that can 
serve as an important resource. More information about travel-related 
immunizations can be found elsewhere in this issue.  
Special Considerations for Refugee Populations 
According to the United Nations Convention Relating to the Status of 
Refugees (Article 1A: 1951), a refugee is “someone who, owing to a well-
founded fear of being persecuted for reasons of race, religion, nationality, 
membership of a particular social group, or political opinion, is outside the 
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country of his nationality, and is unable to or, owing to such fear, is unwilling to 
avail himself of the protection of that country.”25  
Approximately 80,000 refugees arrive annually into the U.S., with over 2 
million arrivals since 1980.26 Refugees bring a unique set of medical issues and 
conditions that must be addressed by the treating healthcare provider.  Prior to 
arrival in the U.S., all refugees undergo an overseas medical examination with 
the purpose of identifying any diseases (i.e. active tuberculosis, leprosy) that 
would preclude travel to the U.S.  Depending on the country of origin, 
vaccinations may also be provided at the time of this exam.   
According to the Immigration and Nationality Act (Section 212), any 
individual seeking admission to the U.S. as either an incoming immigrant, or as 
an immigrant seeking an adjustment of status for permanent U.S. residence 
(green card), is ineligible for admission to the U.S. if they are unable to present 
the appropriate documentation of having received vaccinations against 
‘‘vaccine- preventable diseases, which shall include at least the following 
diseases: Mumps, measles, rubella, polio, tetanus and diphtheria toxoids, 
pertussis, Haemophilus influenzae type B, and hepatitis B, and any other 
vaccinations against vaccine-preventable diseases recommended by the 
Advisory Committee on Immunization Practices (ACIP).’’  Vaccinations given 
overseas are considered acceptable if they have been given at the 
appropriate intervals and age guidelines. 
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All refugees are eligible for adjustment of status after they have lived in 
the U.S. for 1 year.  For this reason, vaccination is an essential piece in the 
medical care of newly arrived refugees to the US.  In addition, in order for 
refugee children to attend school in the US, they must have either appropriate 
documentation of vaccinations provided overseas, or have initiated the 
vaccination series in the U.S.  Due to the large number of vaccinations that are 
required for both children and adults, healthcare providers need to be very 
familiar with the CDC’s guidelines on vaccinations, including child, adolescent, 
adult and catch-up schedules.  As of December 14, 2009, the CDC has new 
criteria that will be used to decide which vaccines will be required as part of the 
immigration process.  The criteria are as follows: 
 (1) The vaccine must be an age- appropriate vaccine as recommended 
by the ACIP for the general U.S. population, and 
 (2) At least one of the following: 
a. The vaccine must protect against a disease that has the 
potential to cause an outbreak. 
b. The vaccine must protect against a disease that has been 
eliminated in the United States or is in the process for elimination in 
the United States. 
Any changes made by the CDC will be reflected in the CDC’s Technical 
Instructions for Panel Physicians for Vaccinations. 
(http://www.cdc.gov/immigrantrefugeehealth)  The current requirements for 
routine vaccination during the immigration process are seen in Table 1 below. 
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International Adoptees and Others Receiving Vaccination Outside the United 
States 
Evidence of immunization prior to coming to the U.S. must be proven by 
written documentation, with the exception of influenza and pneumococcal 
polysaccharide vaccine, for which verbal history is acceptable. Adequate 
protection is most likely if the vaccination history closely matches the U.S. 
immunization schedule with regard to age of administration and immunization 
interval.  Even with documented immunizations, however, it is possible that 
serologic testing may reveal inadequate protection. Repeating of immunizations 
according to the catch-up schedule is an appropriate option to ensure 
protection.8 
Vaccination/revaccination is recommended for MMR and polio. In 
addition, age-appropriate vaccination/revaccination is recommended for Hib, 
HAV, HBV (along with HBsAg testing), varicella (if lacking evidence of immunity), 
pneumococcal conjugate, rotavirus, HPV, and zoster. Alternatively, MMR, 
poliovirus and HAV immunity can be determined through serologic testing 
before deciding to administer these vaccines.8 
Revaccination is also recommended for DTaP, but adverse local reactions 
are more common after the 4th or 5th dose. Therefore, if a severe local reaction 
occurs, IgG titers for tetanus and diphtheria toxins should be obtained before 
deciding to proceed with additional DTaP administrations (while serologic tests 
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exist for tetanus/diphtheria, there are no currently available serologic tests to 
confirm adequate immunity against pertussis). For foreign-born children with 3 or 
more documented doses of DTaP prior to coming to the U.S., it is also 
appropriate to do tetanus/diphtheria serologic testing at initial presentation or 1 
month after a booster dose. If adequate immunity is demonstrated, only 
standard age-appropriate immunizations would be necessary after that point. 
For older persons, Tdap should be administered as appropriate based on 
standard guidelines.8 
 
Summary 
 Despite the great progress that has been made in the U.S. in the last 
century with vaccine-preventable diseases, significant morbidity and mortality is 
seen throughout the world in individuals who have not been vaccinated.  As the 
foreign-born population in the U.S. continues to rise, primary care physicians 
must feel comfortable treating these individuals in a culturally and linguistically-
appropriate manner. 
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Figure 1:  Distribution of estimated annual deaths from vaccine-preventable 
diseases, 2002.9 
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FIGURE 2:  Number and rate* of tuberculosis (TB) cases among U.S.-born and foreign-
born persons, by year --- United States, 1993—2010.15 
 
Figure 3:  Number of TB cases reported among U.S. born and foreign-born 
individuals (1999-2009).5 
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Figure 4: Geographic distribution of chronic hepatitis B virus (HBV) infection – worldwide, 
2006.16 
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Table 1: Requirements for routine vaccination of immigrants examined overseas who are not 
fully vaccinated or lack documentation.27 
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